Clinical Trial

Thermal Ablation of Cervical Metastases From Thyroid Carcinoma

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study will evaluate the clinical response and safety of ultrasound guided percutaneous thermal ablation of lymph node metastases from thyroid carcinoma as an alternative to surgical treatment. The ablation of cervical lymph node metastases from differentiated thyroid carcinoma or medullary thyroid carcinoma will be directed to lesions larger than 0.8 cm, using ultrasound-guided radiofrequency ablation (RFA), laser ablation (LA) or cryoablation (Cryo) techniques, randomly assigned. Clinical and ultrasound monitoring will be carried out during 24 months, with examinations before the ablation procedure, immediately after including contrast-enhanced ultrasound (CEUS) when applicable, and B-mode, color Doppler and Shear-Wave elastography ultrasound follow up with 6, 12, and 24 months.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-08-19; most recent amendment 2025-04-28.
Status change: Recruiting → Active, Not Recruiting 2025-04-28
Status change: Not Yet Recruiting → Recruiting 2021-02-23
Trial Details
NCT Number NCT04522570
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Conditions Thyroid Neoplasia, Well-Differentiated Thyroid Cancer, Medullary Thyroid Cancer, Lymph Node Metastases
Enrollment 84 participants
Start Date 2020-12-14
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-30